Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Recombinant COVID-19 Vaccine NVSI-06-09 in Healthy Adults
NCT05599516Phase 3Unknown
- Sponsor
- Serum Institute of India
- Start
- Nov 2022
- Primary completion
- Oct 2023
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of BIBP-Rec-Vaccine in coronavirus disease 2019 (COVID-19), sponsored by Serum Institute of India. Status: unknown.
02
Drugs
BIBP-Rec-Vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05599516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05599516.